ONCE - Spark Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
61.2800
-0.7300 (-1.18%)
As of 2:41PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close62.0100
Open61.6200
Bid61.2400 x 1000
Ask61.3600 x 800
Day's Range60.7600 - 62.5700
52 Week Range41.0600 - 96.5900
Volume357,560
Avg. Volume706,445
Market Cap2.302B
Beta2.53
PE Ratio (TTM)N/A
EPS (TTM)-7.1120
Earnings DateAug 8, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est69.67
Trade prices are not sourced from all markets
  • Motley Fool2 hours ago

    3 Tough-Luck Tumbles in Healthcare: Are They Buys?

    Spark Therapeutics, Rite Aid, and Alnylam Pharmaceuticals shares have dropped recently, but that doesn't necessarily make all three stocks worth buying.

  • What Does NovoCure’s Valuation Trend Indicate?
    Market Realist6 hours ago

    What Does NovoCure’s Valuation Trend Indicate?

    NovoCure’s (NVCR) net financial expenses increased from $2.18 million in the second quarter of 2017 to $2.86 million in the second quarter. NovoCure’s income tax expenses also increased from $3.46 million in the second quarter of 2017 to $5.56 million in the second quarter.

  • See what the IHS Markit Score report has to say about Spark Therapeutics Inc.
    Markityesterday

    See what the IHS Markit Score report has to say about Spark Therapeutics Inc.

    Spark Therapeutics Inc NASDAQ/NGS:ONCE

  • Reuters2 days ago

    -Express Scripts staking out million dollar gene therapies

    Express Scripts Holding Co built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs. Express Scripts is in talks with biotechnology companies Biomarin Pharmaceutical Inc, Spark Therapeutics Inc and Bluebird Bio Inc to have its specialty pharmaceutical business exclusively distribute their new gene therapies when they are expected to become available in 2019 and 2020, Chief Medical Officer Steve Miller told Reuters in an interview.

  • ACCESSWIRE2 days ago

    Today's Research Reports on Trending Tickers: Spark Therapeutics and PTC Therapeutics

    NEW YORK, NY / ACCESSWIRE / August 15, 2018 / U.S. equities snapped losses on Tuesday, as panic over Turkey’s currency eased and market participants focused on upbeat corporate earnings and strong economic ...

  • Reuters2 days ago

    Express Scripts staking out million-dollar gene therapies

    Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs. Express Scripts is in talks with biotechnology companies Biomarin Pharmaceutical Inc (BMRN.O), Spark Therapeutics Inc (ONCE.O) and Bluebird Bio Inc (BLUE.O) to have its specialty pharmaceutical business exclusively distribute their new haemophilia therapies when they are expected to become available in 2019 and 2020, Chief Medical Officer Steve Miller told Reuters in an interview.

  • What's Next for Spark Therapeutics
    Motley Fool2 days ago

    What's Next for Spark Therapeutics

    This gene therapy biotech has its sights set on a second commercial-stage opportunity

  • See what the IHS Markit Score report has to say about Spark Therapeutics Inc.
    Markit3 days ago

    See what the IHS Markit Score report has to say about Spark Therapeutics Inc.

    Spark Therapeutics Inc NASDAQ/NGS:ONCE

  • 3 Top Biotech Stocks to Buy Right Now
    Motley Fool4 days ago

    3 Top Biotech Stocks to Buy Right Now

    Adding these companies to portfolios today could pay off big-time.

  • TheStreet.com4 days ago

    3 Biotech Stock Favorites to Bet on Today: Top Analysts

    To trade momentum biotech stocks, it's often best to follow the top experts. Using TipRanks' Top-Rated Stocks investor tool, we can see which biotech names float as Wall Street's most recommended stocks today.

  • 3 Beaten-Down Biotech Stocks: Can They Recover?
    Motley Fool5 days ago

    3 Beaten-Down Biotech Stocks: Can They Recover?

    Is there a light at the end of the tunnel?

  • How Analysts Rate Editas Medicine and Peers in August
    Market Realist7 days ago

    How Analysts Rate Editas Medicine and Peers in August

    Editas Medicine (EDIT) is a research-stage genome editing company. Editas makes use of clustered, regularly interspaced, short palindromic repeats (or CRISPR) technology and has developed a proprietary genome editing platform based on it with a product development strategy to chiefly target genetically defined diseases.

  • See what the IHS Markit Score report has to say about Spark Therapeutics Inc.
    Markit8 days ago

    See what the IHS Markit Score report has to say about Spark Therapeutics Inc.

    Spark Therapeutics Inc NASDAQ/NGS:ONCE

  • Investor's Business Daily10 days ago

    Why Spark Therapeutics' Crash On Hemophilia A Led This Rival To Pop

    Spark Therapeutics crashed Tuesday after its hemophilia A study results seemingly lagged a rival treatment from BioMarin Pharmaceutical. Spark plunged 27.8% in high volume.

  • ACCESSWIRE9 days ago

    Today’s Research Reports on Stocks to Watch: Spark Therapeutics and Ekso Bionics

    Shares of Ekso Bionics saw big gains during the trading day but lost almost 11% in after-hours trading. The company reported second quarter results that didn’t hit estimates. Spark Therapeutics, Inc. shares closed down 27.83% on Tuesday, on significant trading volume compared to usual.

  • Investopedia9 days ago

    Despite Recent Volatility, Biotech Stocks Look Poised to Pop

    Biotechnology investors are no strangers to volatility, and Tuesday's price action was no exception. Followers of gene therapy companies watched one of the most popular names in the industry lose approximately one-third of its value due to patient safety concerns. As alluded to above, shares of Spark Therapeutics dropped sharply in Tuesday's trading session due to heightened patient safety concerns surrounding a hemophilia gene therapy trial.

  • Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges
    Zacks9 days ago

    Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges

    The last leg of Q2 earnings in the biotech sector saw Regeneron firing all cylinders. The company also collaborated with bluebird bio, which impressed investors.

  • The Wall Street Journal10 days ago

    [$$] Akouos Gets $50 Million to Fight Hearing Loss With Gene Therapy

    Investors are pumping $50 million into Akouos Inc.’s effort to develop gene therapies for hearing loss. No drugs have been approved in the U.S. to cure hearing loss. About 37.5 million U.S. adults report some trouble hearing, according to the National Institute on Deafness and Other Communication Disorders.

  • Why Weight Watchers International, Tenet Healthcare, and Spark Therapeutics Slumped Today
    Motley Fool10 days ago

    Why Weight Watchers International, Tenet Healthcare, and Spark Therapeutics Slumped Today

    Find out which of these stocks had the biggest losses.

  • Investor's Business Daily10 days ago

    Dow Jones Leads Stocks Higher As Disney Jumps, Global Markets Rally

    China launched a rally across global markets Tuesday, with Etsy, Twilio and Illumina posting early leads in the U.S., as Disney prepared for its report after the close.

  • Why Spark Therapeutics Stock Is Getting Slammed Today
    InvestorPlace10 days ago

    Why Spark Therapeutics Stock Is Getting Slammed Today

    Spark Therapeutics (NASDAQ:ONCE) stock was falling hard on Tuesday following the release of its earnings report for the second quarter of 2018. Spark Therapeutics’s earnings report includes an update concerning the company’s Phase 2 trial of SPK-8011. SPK-8011 is a gene therapy the company is developing to reduce bleeding caused by hemophilia A. The results from this study found that it reduced annualized bleeding rates and annualized infusion rates in all of the 12 patients by 97%.

  • Why Spark's stock price is down 30 percent
    American City Business Journals10 days ago

    Why Spark's stock price is down 30 percent

    The company reported two patients in a study of its hemophilia A gene therapy had an adverse immune response, but with that issue addressed Spark is moving forward late-stage testing of the experimental product.

  • Spark Therapeutics (ONCE) Q2 Earnings Beat Estimates
    Zacks10 days ago

    Spark Therapeutics (ONCE) Q2 Earnings Beat Estimates

    Spark Therapeutics (ONCE) delivered earnings and revenue surprises of 581.40% and -14.44%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • MarketWatch10 days ago

    Spark Therapeutics stock plummets 28% premarket on hemophilia trial's patient safety concerns

    Spark Therapeutics Inc. (ONCE) shares dropped 28% in Tuesday premarket trade after the company said two patients in its hemophilia phase 1/2 trial had a concerning immune response, one of whom was hospitalized as a result. Twelve patient total have been dosed so far in the clinical trial, which is testing the company's gene therapy SPK-9001 in patients with hemophilia B, and the therapy's effect on patients' clotting factor levels was an important outcome.

  • ACCESSWIRE10 days ago

    Today's Research Reports on Trending Tickers: Spark Therapeutics and bluebird bio

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / U.S. markets closed in the green on Monday, as Nasdaq surged for the fifth consecutive session, on a batch of strong corporate earnings, amidst ongoing trade-related ...